The T1D Fund can push cell supply solutions across the finish line in the near term, but it will require a paradigm shift.
UP421 is the first clinical trial to protect insulin-producing cells without immunosuppression in a T1D patient, but how does it fare long term?
Recommendations and actions for Breakthrough T1D to consider in 2026 to make it a truly ‘breakthrough’ year.
The most impactful T1D Practical Cure highlights of 2025.
